File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms

TitleHighlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms
Authors
Bose, PrithvirajXiao, ZhijianHasselbalch, Hans C.Prchal, Josef T.Duan, MinghuiYacoub, AbdulraheemRampal, RaajitKiladjian, Jean-JacquesHobbs, Gabriela S.Tashi, TsewangShimoda, KazuyaKirito, KeitaGill, HarinderHou, Hsin-AnLee, Sung-EunHuang, JianLi, BingQin, AlbertYu, Lennex Hsueh-LinMascarenhas, John O.Mesa, Ruben A.
Issue Date12-Jul-2025
PublisherSpringer
Citation
Current Hematologic Malignancy Reports, 2025, v. 20 How to Cite?
DOI: http://dx.doi.org/10.1007/s11899-025-00752-3
Abstract

MPN Asia 2025 highlighted the growing role of molecular diagnostics and targeted therapeutics in the management of MPNs. Ropeginterferon alfa-2b has emerged as a therapeutic potential across the MPN spectrum. Its early use and personalized strategies are increasingly recognized. Real-world data and regional insights are shaping a more nuanced, globally informed approach to MPN care.

The 8th Annual International Symposium on Myeloproliferative Neoplasms (MPN Asia 2025), held in Beijing, brought together leading hematologists and researchers from across Asia, Europe, and North America to share novel insights into the evolving landscape of Myeloproliferative Neoplasm (MPN) biology and therapeutics. The conference featured data from clinical trials, real-world evidence, and translational research, highlighting an emerging consensus on personalized, molecularly informed treatment strategies.


Persistent Identifierhttp://hdl.handle.net/10722/357864
ISSN
1558-8211
2023 Impact Factor: 2.7
2023 SCImago Journal Rankings: 0.998
ISI Accession Number ID
WOS:001526719100001

 

DC FieldValueLanguage
dc.contributor.authorBose, Prithviraj-
dc.contributor.authorXiao, Zhijian-
dc.contributor.authorHasselbalch, Hans C.-
dc.contributor.authorPrchal, Josef T.-
dc.contributor.authorDuan, Minghui-
dc.contributor.authorYacoub, Abdulraheem-
dc.contributor.authorRampal, Raajit-
dc.contributor.authorKiladjian, Jean-Jacques-
dc.contributor.authorHobbs, Gabriela S.-
dc.contributor.authorTashi, Tsewang-
dc.contributor.authorShimoda, Kazuya-
dc.contributor.authorKirito, Keita-
dc.contributor.authorGill, Harinder-
dc.contributor.authorHou, Hsin-An-
dc.contributor.authorLee, Sung-Eun-
dc.contributor.authorHuang, Jian-
dc.contributor.authorLi, Bing-
dc.contributor.authorQin, Albert-
dc.contributor.authorYu, Lennex Hsueh-Lin-
dc.contributor.authorMascarenhas, John O.-
dc.contributor.authorMesa, Ruben A.-
dc.date.accessioned2025-07-22T03:15:25Z-
dc.date.available2025-07-22T03:15:25Z-
dc.date.issued2025-07-12-
dc.identifier.citationCurrent Hematologic Malignancy Reports, 2025, v. 20-
dc.identifier.issn1558-8211-
dc.identifier.urihttp://hdl.handle.net/10722/357864-
dc.description.abstract<p>MPN Asia 2025 highlighted the growing role of molecular diagnostics and targeted therapeutics in the management of MPNs. Ropeginterferon alfa-2b has emerged as a therapeutic potential across the MPN spectrum. Its early use and personalized strategies are increasingly recognized. Real-world data and regional insights are shaping a more nuanced, globally informed approach to MPN care.<br></p><p>The 8th Annual International Symposium on Myeloproliferative Neoplasms (MPN Asia 2025), held in Beijing, brought together leading hematologists and researchers from across Asia, Europe, and North America to share novel insights into the evolving landscape of Myeloproliferative Neoplasm (MPN) biology and therapeutics. The conference featured data from clinical trials, real-world evidence, and translational research, highlighting an emerging consensus on personalized, molecularly informed treatment strategies.<br></p>-
dc.languageeng-
dc.publisherSpringer-
dc.relation.ispartofCurrent Hematologic Malignancy Reports-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleHighlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1007/s11899-025-00752-3-
dc.identifier.volume20-
dc.identifier.eissn1558-822X-
dc.identifier.isiWOS:001526719100001-
dc.identifier.issnl1558-8211-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats